**4baseCare Secures Additional ₹38 Cr to Close Series B Round at ₹128 Cr**
Months after securing ₹90 Crore, Bengaluru-based healthtech startup 4baseCare has raised an additional ₹38 Crore to close its Series B round at ₹128 Crore. This latest infusion, led by growX Ventures with participation from undisclosed existing investors, underscores the growing investor confidence in the Indian healthtech sector. The funds will be utilised to expand 4baseCare’s genomics laboratory network and scale its precision oncology platform, OncoTwin, internationally.
**About 4baseCare and Its Innovations**
Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare is at the forefront of integrating genomics and AI in oncology care. The startup focuses on personalised cancer treatment by leveraging advanced genomics and bioinformatics. Its platform, OncoTwin, provides clinicians with actionable insights derived from a comprehensive database that combines genomic, clinical, environmental, and lifestyle data. This approach enhances the precision of cancer treatments, catering to the specific needs of individual patients.
**Context and Competitive Landscape**
The funding comes at a time when the healthtech sector in India is experiencing significant growth, driven by technological advancements and increasing healthcare demands. Investors are particularly interested in startups that focus on precision medicine and continuous health optimisation. 4baseCare’s recent funding round follows a trend where other healthtech companies like StrainX Bioworks and Cent have also attracted substantial investments. As the Indian healthtech market is projected to reach $37 billion by 2030, companies offering innovative solutions in healthcare are well-positioned to capture a significant share.
**Implications for India’s Startup Ecosystem**
4baseCare’s successful fundraising highlights the potential of India’s healthtech sector to attract international attention and investment. The startup’s focus on expanding its genomic lab network globally not only signifies its growth ambitions but also sets a precedent for other Indian startups aiming to scale internationally. This move is indicative of a broader trend where Indian startups are increasingly looking beyond domestic markets to fuel their growth, leveraging technological innovations to solve complex global health challenges.
As 4baseCare continues to expand its reach, it is likely to influence other healthtech startups in India to pursue international expansion and invest in advanced technologies like AI and genomics. For investors, 4baseCare’s success story could serve as a case study in identifying promising investment opportunities in the healthtech domain.
Looking ahead, the performance of 4baseCare’s international ventures will be crucial. It will be important to monitor how effectively the company scales its operations and the impact of its precision oncology solutions on global markets. This could provide valuable insights for founders and investors considering similar expansion strategies in the healthtech sector.
